Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the quality of life of intramuscular (IM) Interferon
Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically
Isolated Syndrome (CIS) in a clinical practice setting.